KONINKLIJKE PHILIPS NV (PHG) Financial Ratio Screen

NYSE Healthcare Netherlands USD 26899M
FINANCIAL SCREEN PASSED*
Automated financial screen · activity assessed separately
KONINKLIJKE PHILIPS NV (PHG) passes all available checks in 2 implemented financial-ratio model(s). Its activity assessment is still in progress; this is not a Shariah verdict. Its debt proxy is 29.0% against the model threshold of 30%. The supplied classification is Healthcare (Medical Devices); mixed activities and revenue segments remain part of the activity assessment.

Track PHG screening changes

Get an email when this stock's published screening status or underlying ratios change.

MSCI new-inclusion financial-ratio snapshot

PHG financial screening at a glance

FINANCIAL SCREEN PASSED*Financial ratios shown separately from business review — not a fatwa
Debt ratio
29.0%
Pass vs 30%
Cash ratio
10.4%
Pass vs 30%
Receivables + cash
25.0%
Pass vs 30%
Impermissible income
0.5%
Pass vs 5%

Calculation date: 2026-08-31. Financial period used: December 2025. The ratios are automated proxies inspired by published methodologies; they are not official index determinations.

Independent method comparison

What the available screens say

How MSCI, FTSE and S&P-style screens differ
Request this stock review
MSCI-styleFinancial criteria passedActivity is assessed separately
FTSE/Yasaar-styleFinancial criteria passedActivity is assessed separately
S&P-style provisionalNot yet availableRequired denominator or financial data is incomplete
Business activityAssessment pendingFinancial results do not determine business permissibility
Complete screening result: not yet completeA complete result requires both supported financial criteria and adequate activity evidence. This site does not issue a fatwa or official index decision.
Financial periodDecember 2025Calculation date2026-08-31S&P-style historynot availableLast activity reviewnot yet reviewed

The request button opens your email application with a pre-filled message. HalalStockGuide receives no address or request unless you choose to send it.

Business activity evidence

Activity assessment in progress

The supplied classification (Medical Devices) is only a starting point. Revenue evidence is being assessed before any complete screening conclusion.

Revenue segments: Not yet checked against an SEC annual filing.

Profile description reviewed: Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. It operates through Diagnosis & Treatment, Connected Care, and Personal Health segments. The company provides diagnostic imaging solutions, includes ultrasound business unit, magnetic resonance imaging, computed tomography, and diagnostic x-ray; Image Guided Therapy, including image guided therapy systems and image guided therapy devices. It also offers monitoring, enterprise informatics, and sleep and respiratory care, as well as personal health. Koninklijke Philips N.V. has strategic alliance with WellSpan Health to advanced imaging and diagnostics technology products and platforms. The company was formerly known as Koninklijke Philips Electronics N.V. and changed its name to Koninklijke Philips N.V. in May 2013. Koninklijke Philips N.V. was founded in 1891 and is headquartered in Amsterdam, the Netherlands.

Sources to verify: Secondary company profile and classification · Issuer website · SEC issuer filings

A sector label or company description can flag a risk but cannot establish a compliant-revenue percentage. Only sourced segment disclosures may support that calculation.

Published-ratio reproductions (not certifications)

The table shows implemented MSCI and FTSE/Yasaar-style asset-based models plus a provisional S&P-style leverage reconstruction where a complete 36-month denominator exists. These are independent calculations, not official index results or Shariah determinations. See formulas, sources and limitations.

Based on financial data from December 2025

Standard Debt Ratio Cash Ratio Receivables Income Status
MSCI 29.0%
/ 30%
10.4%
/ 30%
25.0%
/ 30%
0.47%
/ 5%
FINANCIAL SCREEN PASSED*
FTSE 29.0%
/ 33%
10.4%
/ 33%
25.0%
/ 50%
0.47%
/ 5%
FINANCIAL SCREEN PASSED*

Financial Highlights

P/E Ratio
20.7
Forward: 14.5
EPS
$1.33
Dividend Yield
369.0%
Payout: 76.2%
P/B Ratio
2.0
EV/EBITDA
13.5
EV: $32.6B
Revenue
$17.8B
Growth: 0.5%
Beta
0.9
Average volatility
Current Ratio
1.3

Profitability

Gross Margin 45.9%
Operating Margin 14.0%
Net Margin 6.3%
Return on Equity (ROE) 10.2%
Return on Assets (ROA) 4.1%

Cash Flow & Balance Sheet

Operating Cash Flow$1.2B
Free Cash Flow$504M
Total Debt$7.8B
Debt-to-Equity65.0
Current Ratio1.3
Total Assets$26.9B

Price & Trading

Last Close$27.42
50-Day MA$26.87
200-Day MA$27.77
Avg Volume1.1M
Beta0.9
52-Week Range
$23.85
$33.44

Financial data provenance and verification

The displayed fields were imported from yfinance on 2026-08-25 for the financial period December 2025. This is a secondary data feed and can differ from amended or newly filed statements.

Verification rule: check debt, cash, receivables, revenue and interest income against the latest primary filing before relying on an automated ratio.

About KONINKLIJKE PHILIPS NV (PHG)

CEO
Mr. Roy Willem Odilia Jakobs
Employees
63,670
Sector
Healthcare
Industry
Medical Devices
Country
Netherlands
Exchange
NYSE
Market Cap (listing currency)
USD 26899M
Currency
USD

Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. It operates through Diagnosis & Treatment, Connected Care, and Personal Health segments. The company provides diagnostic imaging solutions, includes ultrasound business unit, magnetic resonance imaging, computed tomography, and diagnostic x-ray; Image Guided Therapy, including image guided therapy systems and image guided therapy devices. It also offers monitoring, enterprise informatics, and sleep and respiratory care, as well as personal health. Koninklijke Philips N.V. has strategic alliance with WellSpan Health to advanced imaging and diagnostics technology products and platforms. The company was formerly known as Koninklijke Philips Electronics N.V. and changed its name to Koninklijke Philips N.V. in May 2013. Koninklijke Philips N.V. was founded in 1891 and is headquartered in Amsterdam, the Netherlands.

Popular halal stock checks

Explore other frequently viewed automated stock screens and compare the available financial ratios.

Frequently Asked Questions

Is KONINKLIJKE PHILIPS NV (PHG) halal to invest in?

The current automated result is Financial screen passed; activity assessment pending. It uses available public financial fields and simplified methodology proxies. It is not a fatwa or an official determination by AAOIFI, DJIM, MSCI, S&P, or FTSE.

What is KONINKLIJKE PHILIPS NV's debt ratio?

KONINKLIJKE PHILIPS NV's debt ratio is 29.0% in the MSCI new-inclusion reproduction: total debt divided by total assets, against a 30% threshold. See the methodology page for the official source and limitations.

What are KONINKLIJKE PHILIPS NV's key financial metrics?

KONINKLIJKE PHILIPS NV has a market capitalization of USD 26899M in its listing currency, trailing P/E ratio of 20.7, and revenue of $17.8B. The company maintains a gross margin of 45.9% and a net margin of 6.3%. Return on equity stands at 10.2%.

How often is the screening data updated?

Calculation date: 2026-08-31. Financial period: December 2025. These dates are shown separately because regenerating this page does not refresh the underlying data.

Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.